Multiple SclerosisEXO-MOBILITYNCT07252895
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
A study testing EXOPULSE Suit in Active mode in people with Multiple Sclerosis, run by Otto Bock France SNC at 11 sites in France.
Trial summary
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- EXOPULSE Suit in Active mode
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 77 participants
- Where
- 11 sitesFrance
- Study dates
- 30 Mar 2026to Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Person with a clear Multiple Sclerosis diagnosis according to the 2017 revision of the McDonald criteria since at least 3 months.
- Person with an Expanded Disability Status Scale (EDSS) score ≥ 4 and ≤ 6
- Person with stable walking ability for at least two weeks prior to the inclusion visit (variation at the MSWS-12 questionnaire < 8/100 points)
- Person not treated with fampridine due to contra-indication or adverse events or not respondent or no longer respondent or reluctant to taking drugs
- Person with spasticity at the lower limb(s), attested by a Modified Ashworth Scale ≥ 1+ of at least one of the following muscle groups: quadriceps, hamstrings, triceps surae, tibialis anterior
- Person who never tried EXOPULSE SUIT
Who cannot join
- Person under 18 years old
- Person having a contraindication to using EXOPULSE SUIT
- Person using an electronic life-support equipment, e.g. pacemakers or hight-frequency surgical equipment and person using an ECG equipment
- Person affected by other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
- Person with relapses over the last 3 months before the inclusion
- Person who had a modification of his/her medical treatments of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion
Show all 18Show fewer
- Person who had a new medical treatment of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion
- Person who had an injection of botulinum toxin in at least one of the main muscle groups of the lower limbs over the last 4 months before the inclusion
- Person planning to use a new medical device during the study (ex: ankle-foot orthosis…)
- Person undergoing or planning to undergo an intensive rehabilitation phase
- Person that is part of another study
- Person who cannot be fitted with EXOPULSE SUIT due to inexistent Suitable size of the Suit (eg: BMI>35; user height < 100 cm or > 205cm)
- Person who does not have a smartphone or who cannot or does not want to use his/her smartphone for operating the EXOPULSE App
- Person not available to undergo all medical visits during the study
- Person unable to understand verbal and written instructions in french
- Pregnant person
- Persons under juridical protection
- Prisoners
Trial locations and contacts
11 sites in 1 country. Contact the study team or a site near you to ask about taking part.
11 sites in 1 country
France11 sites, 10 recruiting
- Recruiting
Centre Jacques Calvé Fondation Hopale
Berck, 62 608
Pascal RIGAUX, Dr.
Pascal RIGAUX, Dr.
- Recruiting
CHU Henri Mondor
Créteil, 94000
Samar AYACHE, Pr.
Samar AYACHE, Pr.
- Recruiting
CHU Dijon
Dijon, 21 079
Paul ORNETTI, Pr.
Paul ORNETTI, Pr.
- Recruiting
Clinique Verdaich
Gaillac-Toulza, 31 550
Elsa MAURUC-SOUBIRAC, Dr.
Elsa MAURUC-SOUBIRAC, Dr.
- Recruiting
Hôpital Raymond-Poincaré
Garches, 92380
Djamel BENSMAIL, Pr.
Djamel BENSMAIL, Pr.
- Active, not recruiting
Hopital Saint Philibert
Lomme, 59462
- Recruiting
Centre Médical Germaine REVEL
Lyon, 69 440
Vivien RAYNAUD, Dr.
Vivien RAYNAUD, Dr.
- Not yet recruiting
Hôpital L'Archet
Nice, 62 000
Audrey ALLAMANDI, Dr.
Audrey ALLAMANDI, Dr.
- Recruiting
Pole MPR Saint Hélier
Rennes, 35000
Philippe GALLIEN, Dr.
Philippe GALLIEN, Dr.
- Recruiting
Hôpital Henry Gabrielle
Saint-Genis-Laval, 69 230
Sophie JACQUIN COURTOIS, Dr.
Sophie JACQUIN COURTOIS, Dr.
- Recruiting
Hôpital de Hautepierre
Strasbourg, 67200
Jérôme DE SEZE, Pr.
Jérôme DE SEZE, Pr.
About this study
Official title: Walking Ability of Patients With Multiple Sclerosis Using the EXOPULSE Suit: Randomized Controlled Crossover Trial
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.
This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis, including improvements in walking ability.
Read the detailed description
Lower limb function is perceived as essential by individuals with multiple sclerosis. The loss of walking ability is a major physical manifestation among individuals with an EDSS score between 4 and 7 and negatively impacts activities of daily living and employment. Various therapeutic options can be proposed to maintain or improve mobility, such as rehabilitation-which is an essential and irreplaceable component of the clinical care pathway-or treatments aimed at reducing symptoms such as spasticity, fatigue, or pain.
Fampridine is the only treatment exclusively intended to improve walking ability. However, not all individuals can benefit from this medication due to contraindications, side effects, lack of response, or loss of response over time. Some individuals also prefer to avoid drug-based treatments.
The EXOPULSE Suit is a class IIa-certified electrical medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.
The EXOPULSE Suit may represent an alternative for improving walking ability in individuals who cannot be treated with Fampridine.
This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis and to demonstrate improved walking ability with the EXOPULSE Suit compared with a sham condition.
- Conditions
- Multiple Sclerosis
- Being tested
- EXOPULSE Suit in Active mode, EXOPULSE Suit in Sham mode
- Keywords
- Multiple Sclerosis, neuromodulation, suit, walking ability, multi-site electrical stimulation
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EXOPULSE Suit in Active modeDevice
The EXOPULSE Suit in Active mode stimulates the targeted muscles during the whole 60-minutes cession
EXOPULSE Suit in Sham modeDevice
The EXOPULSE Suit in Sham mode stimulates the targeted muscles during the first minute of the cession then is off during the 59 minutes left.
| Study group | Role | What they receive |
|---|---|---|
| EXOPULSE Suit Active then EXOPUSLE Suit sham | Other | The participant is fist using the EXOPULSE Suit in Active mode for 4 weeks, then he has a 4-weeks wash-out period, then he is using the EXOPULSE Suit in a sham mode for 4 weeks. Receives: Device: EXOPULSE Suit in Active mode; Device: EXOPULSE Suit in Sham mode |
| EXOPULSE Suit in sham mode then EXOPULSE Suit in Active mode | Other | The participant is first using the EXOPUISE Suit in sham mode for 4 weeks, then he has a 4-weeks wash-out phase, the he is using the EXOPULSE Suit in Active mode for 4 weeks. Receives: Device: EXOPULSE Suit in Active mode; Device: EXOPULSE Suit in Sham mode |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Multiple Sclerosis Walking Scale 12 (MSWS-12)
The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a 12-item assessment tool designed to measure the impact of multiple sclerosis (MS) symptoms on patients' walking and balance ability, through a series of questions about various daily activities performed over the previous two weeks. Patients are asked to rate the impact of MS on their mobility using a five-point Likert scale, ranging from 1, indicating "no im-pact", to 5, meaning "extremely significant impact". The final score is obtained by adding the responses to the 12 questions (with a sum ranging from 12 to 60). This sum is then converted to a scale of 0 to 100, where a higher score reflects a greater impact of symptoms on the patient's walking ability.
Measured: 28 days
Secondary outcomes (8)
10 Meters Walk Test (10MWT)
The 10MWT is a performance measure that assesses walking speed in meters per second over a short dis-tance. A high score indicates a fast-walking speed. At a comfortable speed, the patient is asked to walk over 10 meters, plus 2 meters at the beginning and at the end for acceleration and deceleration.
Measured: 28 days
2-minute Walk Test (2MWT)
The 2-minute Walk test is a measurement of endurance that assesses the maximum walking distance over 2 minutes. A long walking distance reflects good endurance.
Measured: 28 days
Timed-up and go Test (TUG)
The Timed Up and Go (TUG) test is a validated tool in people with MS to assess functional mobility. It measures the time it takes a person to get up from a chair (without the help of the hands), walk 3 meters, turn around a cone / mark on the floor, return to the chair, and sit back down. Patients are instructed to complete the course as safely and quickly as possible. If needed, patients are allowed to use assistive devices while performing the task. They are given 2 trials to complete the TUG test and the computed time across the 2 trials is the final score.
A high value reflects an increased risk of falling.
Measured: 28 days
Visual Analog Scale - Fatigue (VAS - Fatigue)
The VAS is a measurement tool where the patient rates his fatigue level by marking a point on a 10 cm line that represents a continuum between "no fatigue" and "worst possible fatigue". The measurement (in mm) between the left end of the line and the mark done by the patient represents the level of fatigue perceived by the patient. The score is then expressed by a note between 0 and 10, 10 being the worst pos-sible fatigue.
Measured: 28 days
The Modified Ashworth Scale (MAS)
The Modified Ashworth Scale (MAS) is a revised version of the original Ashworth Scale that measures spasticity in patients with lesions to the central nervous system.
MAS measures the increase in muscle tone by assigning a grade of spasticity from 0 to 4. The grade is assigned by moving a joint/muscle through a high velocity quick stretch.
MAS grades:
0 : No increase in muscle tone
1 : Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
1+ : Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement) 2 : More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 : Considerable increase in muscle tone passive, movement difficult 4 : Affected part(s) rigid in flexion or extension
Measured: 28 days
The Multiple Sclerosis Impact Scale 29-items (MSIS-29)
The Multiple Sclerosis Impact Scale 29-items (MSIS-29) is 29-items' self-questionnaires that measure the physical and psychological impact of MS on day-to-day life in the past two weeks. . It comprises 20 items associated with a physical scale and a 9-items scale with a psychological scale. Each item has 5 response options going from 1 "not at all" to 5 "extremely". Each of the two scales are scored by summing the response across items, then converting to a 0-100 scale where 100 indicates a greater impact of disease on daily function.
The physical impact score is computed by summing items number 1-20 inclusive. This score can then be transformed to a score on a scale of 0 -100 using this formula: (100*(observed score-20))/(100-20).
The psychological impact score is computed by summing items number 21-29 inclusive. This score can then be transformed to a score on a scale of 0 -100 using this formula: (100*(observed score-9)/(45-9).
Measured: 28 days
The EuroQol - 5 Dimensions -5 levels (EQ-5D-5L)
The EuroQol - 5 Dimensions -5 levels (EQ-5D-5L) is a scale developed by the EuroQol group that assesses quality of life through 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxie-ty/depression. Each dimension has 5 levels going from "no problems" to "extreme problems". Health status can be defined by an index value that goes between 0 and 1. It expresses how is the health status, according to preferences of the general population of a given country. Health status is also expressed by the EQ VAS (Visual Analogue Scale). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labeled 'The best health you can imagine' and 'The worst health you can imagine'. VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgment.
Measured: 28 days
Visual Analog Scale - Pain (VAS - Pain)
The VAS is a measurement tool where the patient rates his perceived general pain level by marking a point on a 10 cm line that represents a continuum between "no pain" and "worst possible pain". The measurement (in mm) between the left end of the line and the mark done by the patient represents the level of pain perceived by the patient. The score is then expressed by a note between 0 and 10, 10 being the worst possible pain.
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2025
- Study start30 Mar 2026
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Each participant is his/her own control
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 77 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Otto Bock France SNC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Samar AYACHE, Pr, Study chair, CHU Henri MondorDjamel BENSMAIL, Pr, Study chair, Hôpital Raymond PoincaréJérôme DE SEZE, Pr, Study chair, Hôpital de HautepierreVolker LIMMROTH, Pr, Study chair, Klinik für Neurologie Köln-Merheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07252895
- Sponsor's protocol ID
- BP-11-PT-010
- Acronym
- EXO-MOBILITY
- Status last verified
- Mar 2026
- First submitted
- 19 Nov 2025
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Walking Ability of Patients With Multiple Sclerosis Using the EXOPULSE Suit: Randomized Controlled Crossover Trial
- ClinicalTrials.gov ID
- NCT07252895
- Acronym / sponsor ID
- EXO-MOBILITY / BP-11-PT-010
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, neuromodulation, suit, walking ability, multi-site electrical stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 77 participants (estimated)
- Lead sponsor
- Otto Bock France SNCIndustry (pharma, biotech, devices)
- Study start
- 30 Mar 2026 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 28 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.
This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis, including improvements in walking ability.
Detailed description
Lower limb function is perceived as essential by individuals with multiple sclerosis. The loss of walking ability is a major physical manifestation among individuals with an EDSS score between 4 and 7 and negatively impacts activities of daily living and employment. Various therapeutic options can be proposed to maintain or improve mobility, such as rehabilitation-which is an essential and irreplaceable component of the clinical care pathway-or treatments aimed at reducing symptoms such as spasticity, fatigue, or pain.
Fampridine is the only treatment exclusively intended to improve walking ability. However, not all individuals can benefit from this medication due to contraindications, side effects, lack of response, or loss of response over time. Some individuals also prefer to avoid drug-based treatments.
The EXOPULSE Suit is a class IIa-certified electrical medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.
The EXOPULSE Suit may represent an alternative for improving walking ability in individuals who cannot be treated with Fampridine.
This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis and to demonstrate improved walking ability with the EXOPULSE Suit compared with a sham condition.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Each participant is his/her own control
| Arm | Type | Receives |
|---|---|---|
| EXOPULSE Suit Active then EXOPUSLE Suit sham | Other | Device: EXOPULSE Suit in Active mode, Device: EXOPULSE Suit in Sham modeThe participant is fist using the EXOPULSE Suit in Active mode for 4 weeks, then he has a 4-weeks wash-out period, then he is using the EXOPULSE Suit in a sham mode for 4 weeks. |
| EXOPULSE Suit in sham mode then EXOPULSE Suit in Active mode | Other | Device: EXOPULSE Suit in Active mode, Device: EXOPULSE Suit in Sham modeThe participant is first using the EXOPUISE Suit in sham mode for 4 weeks, then he has a 4-weeks wash-out phase, the he is using the EXOPULSE Suit in Active mode for 4 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Person with a clear Multiple Sclerosis diagnosis according to the 2017 revision of the McDonald criteria since at least 3 months.
- Person with an Expanded Disability Status Scale (EDSS) score ≥ 4 and ≤ 6
- Person with stable walking ability for at least two weeks prior to the inclusion visit (variation at the MSWS-12 questionnaire < 8/100 points)
- Person not treated with fampridine due to contra-indication or adverse events or not respondent or no longer respondent or reluctant to taking drugs
- Person with spasticity at the lower limb(s), attested by a Modified Ashworth Scale ≥ 1+ of at least one of the following muscle groups: quadriceps, hamstrings, triceps surae, tibialis anterior
Key exclusion criteria (18 listed)
- Person under 18 years old
- Person having a contraindication to using EXOPULSE SUIT
- Person using an electronic life-support equipment, e.g. pacemakers or hight-frequency surgical equipment and person using an ECG equipment
- Person affected by other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
- Person with relapses over the last 3 months before the inclusion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EXOPULSE Suit in Active modeThe EXOPULSE Suit in Active mode stimulates the targeted muscles during the whole 60-minutes cession | Device | EXOPULSE Suit Active then EXOPUSLE Suit sham, EXOPULSE Suit in sham mode then EXOPULSE Suit in Active mode |
| EXOPULSE Suit in Sham modeThe EXOPULSE Suit in Sham mode stimulates the targeted muscles during the first minute of the cession then is off during the 59 minutes left. | Device | EXOPULSE Suit Active then EXOPUSLE Suit sham, EXOPULSE Suit in sham mode then EXOPULSE Suit in Active mode |
Primary outcome
The Multiple Sclerosis Walking Scale 12 (MSWS-12)
Time frame: 28 days
The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a 12-item assessment tool designed to measure the impact of multiple sclerosis (MS) symptoms on patients' walking and balance ability, through a series of questions about various daily activities performed over the previous two weeks. Patients are asked to rate the impact of MS on their mobility using a five-point Likert scale, ranging from 1, indicating "no im-pact", to 5, meaning "extremely significant impact". The final score is obtained by adding the responses to the 12 questions (with a sum ranging from 12 to 60). This sum is then converted to a scale of 0 to 100, where a higher score reflects a greater impact of symptoms on the patient's walking ability.
8 secondary outcomes
10 Meters Walk Test (10MWT)
Time frame: 28 days
2-minute Walk Test (2MWT)
Time frame: 28 days
Timed-up and go Test (TUG)
Time frame: 28 days
Visual Analog Scale - Fatigue (VAS - Fatigue)
Time frame: 28 days
The Modified Ashworth Scale (MAS)
Time frame: 28 days
The Multiple Sclerosis Impact Scale 29-items (MSIS-29)
Time frame: 28 days
The EuroQol - 5 Dimensions -5 levels (EQ-5D-5L)
Time frame: 28 days
Visual Analog Scale - Pain (VAS - Pain)
Time frame: 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Samar AYACHE, Pr study chair
CHU Henri Mondor
Djamel BENSMAIL, Pr study chair
Hôpital Raymond Poincaré
Jérôme DE SEZE, Pr study chair
Hôpital de Hautepierre
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EXOPULSE Suit in Active mode in people with Multiple Sclerosis, run by Otto Bock France SNC at 11 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aurelie LACROIX, Ing. (0033 (0)7 86 29 52 03, aurelie.lacroix@ottobock.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Multiple Sclerosis Walking Scale 12 (MSWS-12) (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.